Transient Decrease of Insulin Secretion after COVID-19 Infection in a Patient with Hyperosmolar Hyperglycemic Syndrome

Ken-ichi Muramatsu¹, Ikuto Takeuchi¹, Soichiro Ota¹ and Youichi Yanagawa^1,

¹Department of Acute Critical Care Medicine, Juntendo Shizuoka Hospital, Izunokuni, Japan

Cite this paper:
Ken-ichi Muramatsu, Ikuto Takeuchi, Soichiro Ota and Youichi Yanagawa. Transient Decrease of Insulin Secretion after COVID-19 Infection in a Patient with Hyperosmolar Hyperglycemic Syndrome. American Journal of Medical Case Reports. 2023; 11(2):37-40. doi: 10.12691/ajmcr-11-2-8

Abstract

A 52-year-old male was transported to a local medical facility due to unconsciousness and involuntary movement. His past history included only hypertension. He consumed over 2 L of soft drink per day. His body mass index was 34. As he had hyperosmolar hyperglycemic syndrome and COVID-19 infection, he was transferred to our department. On arrival, he was in a coma and pre-shock state. He was therefore intubated. Initially, his blood C-peptide level was low, and he showed hyperglycemia with ketosis. Whole body computed tomography (CT) showed pneumonia. He was diagnosed with hyperosmolar hyperglycemic syndrome with ketosis, COVID-19 infection, convulsion, hemoconcentration, liver dysfunction, rhabdomyolysis, pancreatitis, renal failure and hypernatremia. He was admitted to the intensive care unit, where he was successfully treated. His blood C-peptide returned to the normal range (2.2 ng/mL) on day 20, and he returned to the local medical facility on day 21. This is the first report of transient decrease in insulin secretion after COVID-19 infection in a patient with a combination hyperosmolar hyperglycemic syndrome and ketosis. Further prospective studies are needed to clarify the characteristics of the insulin secretion function following COVID-19 infection.

Keywords:
COVID-19 soft drink hyperglycemic hyperosmolar syndrome c-peptide

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Schiano C, Grimaldi V, Scognamiglio M, Costa D, Soricelli A, Nicoletti GF, Napoli C. Soft drinks and sweeteners intake: Possible contribution to the development of metabolic syndrome and cardiovascular diseases. Beneficial or detrimental action of alternative sweeteners? Food Res Int. 2021 Apr; 142: 110220.
[2]	Bray GA, Popkin BM. Dietary sugar and body weight: have we reached a crisis in the epidemic of obesity and diabetes?: health be damned! Pour on the sugar. Diabetes Care. 2014 Apr; 37(4): 950-6.
[3]	Tsuchiya S, Sawada S, Takeda K, Takahashi K, Nakajima T, Kohata M, Kurosawa S, Satake C, Imai J, Kikuchi K, Aiba S, Katagiri H. Eruptive xanthomas in a patient with soft-drink diabetic ketosis and apolipoprotein E4/2. Endocr J. 2019 Jan 28; 66(1): 107-114.
[4]	Tanaka K, Moriya T, Kanamori A, Yajima Y. Analysis and a long-term follow up of ketosis-onset Japanese NIDDM patients. Diabetes Res Clin Pract. 1999 May; 44(2): 137-46.
[5]	Zhou Y, Chi J, Lv W, Wang Y. Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (Covid-19). Diabetes Metab Res Rev. 2021 Feb; 37(2): e3377.
[6]	Erener S. Diabetes, infection risk and COVID-19. Mol Metab. 2020 Sep; 39: 101044.
[7]	Ji N, Zhang M, Ren L, Wang Y, Hu B, Xiang J, Gong Y, Wu C, Qu G, Ding W, Yin Z, Li S, Wang Z, Zhou L, Chen X, Ma Y, Tang J, Liu Y, Liu L, Huang M. SARS- CoV-2 in the pancreas and the impaired islet function in COVID-19 patients. Emerg Microbes Infect. 2022 Dec; 11(1): 1115-1125.
[8]	Boddu SK, Aurangabadkar G, Kuchay MS. New onset diabetes, type 1 diabetes and COVID-19. Diabetes Metab Syndr. 2020 Nov-Dec; 14(6): 2211-2217.
[9]	Akkuş G. Newly-onset Autoimmune Diabetes Mellitus triggered by Covid 19 infection: A case based review. Endocr Metab Immune Disord Drug Targets. 2022 Oct 4.
[10]	Omotosho YB, Ying GW, Stolar M, Mallari AJP. COVID-19-Induced Diabetic Ketoacidosis in an Adult with Latent Autoimmune Diabetes. Cureus. 2021 Jan 13; 13(1): e12690.
[11]	Novac CN, Boboc AA, Nastac C, Balgradean M, Radulian G. Ketoacidosis Onset of Diabetes on a Patient with Normal C-Peptide Value. Maedica (Bucur). 2021 Jun; 16(2): 320-324.
[12]	Wu XY, She DM, Wang F, Guo G, Li R, Fang P, Li L, Zhou Y, Zhang KQ, Xue Y. Clinical profiles, outcomes and risk factors among type 2 diabetic inpatients with diabetic ketoacidosis and hyperglycemic hyperosmolar state: a hospital-based analysis over a 6-year period. BMC Endocr Disord. 2020 Dec 14; 20(1): 182.
[13]	Ilias I, Diamantopoulos A, Pratikaki M, Botoula E, Jahaj E, Athanasiou N, Tsipilis S, Zacharis A, Vassiliou AG, Vassiliadi DA, Kotanidou A, Tsagarakis S, Dimopoulou I. Glycemia, Beta-Cell Function and Sensitivity to Insulin in Mildly to Critically Ill Covid-19 Patients. Medicina (Kaunas). 2021 Jan 14; 57(1): 68.
[14]	Chaithongdi N, Subauste JS, Koch CA, Geraci SA. Diagnosis and management of hyperglycemic emergencies. Hormones (Athens). 2011 Oct-Dec; 10(4): 250-60.